Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prehabilitation in lung cancer patients undergoing lung resection surgery (Fit4LungNeo): study protocol.

Contemporary clinical trials communications·2026
Same author

Corrigendum to "European experience on oncological outcomes of patients with early stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" [Lung Cancer J. 217 (2026) 109410].

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Corrigendum to "European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" Published in [Lung Cancer https://doi.org/10.1016/j.lungcan.2026.109410].

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Layer‑by‑layer biointerface engineering of biopolymer-nanoparticle hybrid coatings for durable antifouling and antibiofilm performance.

Colloids and surfaces. B, Biointerfaces·2026
Same author

European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

A Retrospective Analysis on Level of Suction in Digital Drainage Devices After Video-assisted Lobectomy in a Thoracic Surgery Centre.

Portuguese journal of cardiac thoracic and vascular surgery·2026

Related Experiment Video

Updated: May 8, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.4K

Pemphigus vulgaris Treated With Rituximab: A Case Report.

Guilherme N Faria1, Pedro Fernandes2, Diana Coelho3

  • 1Famiy Medicine, Centro de Saúde do Porto da Cruz, Serviço de Saúde da Região Autónoma da Madeira (SESARAM), Funchal, PRT.

Cureus
|December 27, 2024
PubMed
Summary
This summary is machine-generated.

Rituximab (RTX) effectively treated severe pemphigus vulgaris (PV) unresponsive to other therapies. This B-lymphocyte targeting antibody achieved complete remission, suggesting its potential as a first-line treatment for severe PV.

Keywords:
auto-imune diseasesbiologic therapiespemphigus in adultspemphigus vulgarisrituximab therapy

More Related Videos

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.4K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Related Experiment Videos

Last Updated: May 8, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.4K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.4K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Area of Science:

  • Immunodermatology
  • Autoimmune Blistering Diseases
  • Pharmacological Therapies

Background:

  • Pemphigus vulgaris (PV) is a severe autoimmune blistering disease.
  • Conventional therapies often fail in severe or refractory cases.
  • Rituximab (RTX), a B-lymphocyte depleting antibody, offers a targeted therapeutic approach.

Observation:

  • A 44-year-old female with severe PV (PDAI score 66) presented with extensive mucocutaneous lesions.
  • The patient had a history of unresponsiveness to multiple conventional treatments.
  • RTX was administered in two infusions, two weeks apart, with no complications.

Findings:

  • Complete remission of PV lesions was achieved within four months of RTX treatment.
  • This case demonstrates RTX efficacy in a patient with severe, treatment-refractory PV.
  • The Pemphigus Disease and Area Index (PDAI) score significantly improved post-treatment.

Implications:

  • RTX shows promise as a potential first-line therapy for severe pemphigus vulgaris.
  • Further research is needed to assess RTX's long-term efficacy, safety, and relapse rates.
  • Consideration of RTX's cost and immunosuppressive potential is crucial for clinical feasibility.